In conclusion, our data show that inhibition of HDAC3 ameliorates spatial memory impairment and improves AD‐related neuropathogenesis, while HDAC3 overexpression increases the amyloid burden in AD mice, which suggests that inhibition of HDAC3 is a potential therapy for the treatment of AD. The gene discussed is HDAC3; the disease is amyloidosis.